What Is Triptorelin?
Triptorelin is a synthetic GnRH (gonadotropin-releasing hormone) agonist — a decapeptide that binds GnRH receptors in the pituitary with significantly higher affinity and longer duration than endogenous GnRH. At low doses administered as a single pulse, triptorelin triggers a robust, physiological LH and FSH surge, which stimulates downstream testosterone production. This mechanism has made it a research tool for HPTA (hypothalamic-pituitary-testicular axis) restart following suppression from anabolic steroid use, SARMs, or other exogenous testosterone — where it is used as a single 100 mcg subcutaneous injection to "reset" the axis.
Mechanism: Pulsatile vs. Continuous Dosing
The paradox of GnRH agonists is dose- and frequency-dependent: a single pulse stimulates gonadotropin release (the desired HPTA restart mechanism), while continuous or depot administration causes GnRH receptor downregulation and pituitary desensitization — the same mechanism used in prostate cancer treatment to achieve medical castration. This is why the research HPTA restart protocol uses a single 100 mcg injection rather than ongoing dosing. Clinical depot forms (3.75 mg IM monthly) achieve the opposite effect and are not relevant to HPTA restart research.
HPTA Restart Research
The single-dose triptorelin HPTA restart protocol (100 mcg SubQ) originated from clinical observations and has been adopted in the research community as an alternative to traditional post-cycle therapy (clomiphene, tamoxifen). The rationale: a single GnRH agonist pulse at the pituitary level resets central suppression more directly than SERMs acting at the hypothalamic level. LH and FSH typically surge within 2–4 hours post-injection, triggering testicular steroidogenesis. Recovery of endogenous testosterone production varies by individual, prior suppression depth, and duration.
Quick Reference
Member reference tables summarize the compound's research parameters.
Research Indications
The primary research application is HPTA axis restoration following suppression by exogenous androgens, SARMs, or other HPT-suppressive compounds. Secondary applications include research into pulsatile GnRH signaling dynamics, male hypogonadotropic hypogonadism, and as a reference compound for studying GnRH receptor pharmacology.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.
This member section describes parameters reported in the research literature.
Peptide Interactions
This member section summarizes reported compound interactions and evidence limitations.
Reported Research Time Points
This member section summarizes reported research time points.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
This member section discusses research safety considerations and uncertainties.
Quality Indicators
Research Citations
- Kaminetsky et al. (2009) — Single-dose GnRH agonist triptorelin for testosterone deficiency: HPTA restart pilot
Journal of Sexual Medicine - Shankara-Narayana et al. (2020) — GnRH analogs for HPTA recovery after androgen use: mechanisms and protocols
Clinical Endocrinology - Rahnema et al. (2014) — Anabolic steroid-induced hypogonadism: diagnosis and treatment
Fertility and Sterility - Fontana et al. (2004) — Short-acting triptorelin for pituitary stimulation: pharmacodynamic profile
European Journal of Endocrinology